Suchergebnisse - "Halpin, David M G"

PubPharm (13)

1

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation : a retrospective cohort study

enthalten in: Respiratory research | 2023

von Ismaila, A. | Rothnie, K. | Wood, R. | +8

ErratumIn: Respir Res. 2024 Apr 1;25(1):152. - PMID 38561735

2

A Response to : Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis"

enthalten in: Advances in therapy | 2023

von Ismaila, A. | Haeussler, K. | Malmenäs, M. | +5

CommentOn: Adv Ther. 2022 Sep;39(9):3957-3978. - PMID 35849317

3

Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease : Post hoc analysis of the IMPACT trial

enthalten in: Respirology (Carlton, Vic.) | 2022

von Thompson, P. | Criner, G. | Dransfield, M. | +9

CommentIn: Respirology. 2022 Dec;27(12):1006-1007. - PMID 36031687

4

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD : IMPACT trial post hoc analysis

enthalten in: Respiratory medicine | 2022

von Bardsley, S. | Criner, G. | Halpin, D. | +12

5

Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease : A Network Meta-Analysis

enthalten in: Advances in therapy | 2022

von Ismaila, A. | Haeussler, K. | Czira, A. | +11

ErratumIn: Adv Ther. 2022 Sep 2;:. - PMID 36056291

6

Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD : A Network Meta-Analysis

enthalten in: Advances in therapy | 2022

von Ismaila, A. | Haeussler, K. | Czira, A. | +10

CommentIn: Adv Ther. 2023 May;40(5):2549-2555. - PMID 37004641

7

Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD : A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial

enthalten in: Chest | 2021

von Hanania, N. | Mannino, D. | Criner, G. | +12

CommentIn: Chest. 2021 Mar;159(3):895-896. - PMID 33678268

8

The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2020

von Han, M. | Criner, G. | Dransfield, M. | +11

CommentIn: Am J Respir Crit Care Med. 2020 Nov 1;202(9):1202-1204. - PMID 32758097

9

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

enthalten in: American journal of respiratory and critical care medicine | 2020

von Lipson, D. | Crim, C. | Criner, G. | +17

CommentIn: Am J Respir Crit Care Med. 2020 Jun 15;201(12):1463-1464. - PMID 32212973

10

Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD : results on cardiovascular safety from the IMPACT trial

enthalten in: Respiratory research | 2020

von Day, N. | Kumar, S. | Criner, G. | +13